High-purity Gonadorelin decapeptide is available for qualified academic, institutional, and private laboratory environments conducting endocrinology research. PX1 Research provides fully characterized, USA-manufactured research peptides supported by lot-specific certificates of analysis, high-performance liquid chromatography (HPLC), mass spectrometry (MS), and rigorous endotoxin quantification.
High-purity Gonadorelin decapeptide is available for qualified academic, institutional, and private laboratory environments conducting endocrinology research. PX1 Research provides fully characterized, USA-manufactured research peptides supported by lot-specific certificates of analysis, high-performance liquid chromatography (HPLC), mass spectrometry (MS), and rigorous endotoxin quantification.
Gonadorelin injectable for sale across academic and institutional suppliers refers exclusively to synthetic gonadotropin-releasing hormone (GnRH) formulated as a lyophilized peptide powder for in vitro assay systems and preclinical animal research. It is intended strictly for laboratory investigation into hypothalamic-pituitary-gonadal axis receptor binding and signaling.
When purchasing research compounds for controlled laboratory experiments, scientists must prioritize verification mechanisms including third-party mass spectrometry identity confirmation, RP-HPLC purity analytical reports, and endotoxin limit assays. PX1 Research synthesizes Gonadorelin in domestic, ISO 17025-accredited, GMP-compliant facilities to ensure minimal lot-to-lot variability across biochemical screens.
Gonadorelin is a synthetic decapeptide identical in primary amino acid sequence to native endogenous gonadotropin-releasing hormone (GnRH), also designated as luteinizing hormone-releasing hormone (LHRH). Its structural formula is PyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, featuring an N-terminal pyroglutamic acid modification and a C-terminal glycinamide residue. These end-terminal modifications are essential for preserving molecular stability against non-specific aminopeptidases and carboxypeptidases during in vitro incubations.
With a molecular weight of approximately 1182.3 Da, Gonadorelin exhibits high solubility in aqueous buffer systems, polar organic solvents, and standard cell culture media. In laboratory settings, researchers evaluating research peptides evaluate the structural integrity of the decapeptide using reverse-phase high-performance liquid chromatography (RP-HPLC) coupled with electrospray ionization mass spectrometry (ESI-MS). The precise spatial conformation of the decapeptide permits high-affinity binding to the G-protein coupled GnRH receptor (GnRHR) located on anterior pituitary gonadotrope cell membranes.
In preclinical model systems, Gonadorelin operates as a full agonist at the human and mammalian GnRH receptor. Binding to GnRHR initiates a conformational change that activates Gq/11 class heterotrimeric G-proteins. This activation stimulates phospholipase C beta (PLCβ), which catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two key intracellular second messengers: inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG).
The generation of IP3 triggers rapid calcium ion mobilization from the endoplasmic reticulum into the cytosol. Elevated intracellular free calcium, combined with DAG-mediated activation of protein kinase C (PKC) isoforms, induces exocytosis of pre-stored gonadotropin vesicles. In vitro pituitary cell culture assays demonstrate that this cascade leads to the regulated release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Investigating these signal transduction pathways provides critical insight into feedback inhibition mechanisms within the hypothalamic-pituitary-gonadal (HPG) axis.
A central focus of preclinical literature surrounding Gonadorelin is the differential biological response elicited by pulsatile versus continuous ligand exposure. In vitro perfusion chambers and primary pituitary cell cultures indicate that intermittent, pulsatile administration of Gonadorelin maintains cell surface receptor density and promotes sustained downstream LH and FSH transcription.
Conversely, continuous administration of high-concentration Gonadorelin leads to rapid desensitization of the GnRH signaling pathway. Continuous receptor occupation drives receptor phosphorylation via G-protein coupled receptor kinases (GRKs), recruiting beta-arrestin proteins that facilitate endocytosis and internal sequestration of the GnRH receptor complex. This down-regulation suppresses downstream gonadotropin synthesis and secretion, a phenomenon widely studied in hormone-dependent oncology and reproductive biology research. Researchers seeking to map receptor trafficking often utilize analytical purity testing to confirm that ligand concentrations remain precise throughout prolonged perfusion protocols.
When designing comparative endocrine assays, investigators frequently evaluate native-sequence Gonadorelin alongside synthetic nonapeptide and decapeptide analogs modified for altered receptor affinity or enzymatic half-life. Substituted agonists demonstrate distinct pharmacodynamic profiles due to structural modifications at position 6 (replacing Gly with D-amino acids) and position 10 (proline ethylamide substitution).
For instance, triptorelin incorporates D-tryptophan at position 6, increasing metabolic half-life and GnRHR binding affinity compared to native Gonadorelin. Similarly, leuprolide utilizes a D-leucine substitution to achieve prolonged receptor occupancy, accelerating pituitary desensitization protocols. While native Gonadorelin rapidly undergoes enzymatic degradation via endopeptidases—making it ideal for short-acting, pulsatile baseline studies—modified analogs like triptorelin and leuprolide serve as bench benchmarks for maximum receptor suppression models in comparative research.
Proper preparation of lyophilized Gonadorelin is vital to maintain peptide chain stability, prevent aggregation, and ensure reproducible assay outcomes. Upon receiving the sterile vial, researchers should centrifuge the container briefly at low speed (1,000 x g for 30 seconds) to consolidate the lyophilized cake at the bottom of the vial before removing the seal.
Reconstitution should be performed using sterile, laboratory-grade diluents under a laminar flow hood. For short-term assays or tissue culture applications, sterile 0.9% sodium chloride or phosphate-buffered saline (PBS, pH 7.4) is recommended. When preparing stock solutions for multi-day protocols, adding bacteriostatic water containing 0.9% benzyl alcohol prevents bacterial contamination during repeat sampling. The diluent should be gently trickled down the inner glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl mixing is recommended; aggressive vortexing must be avoided to prevent shear-induced peptide aggregation and secondary structure denaturation. For expanded reconstitution protocols across various molecular weights, consult our reconstitution guide.
Lyophilized Gonadorelin powder remains stable at -20°C for up to 24 months when protected from light and moisture ingress. Storage at -80°C is advisable for long-term institutional repository storage. Vials should be kept in desiccated containers to prevent atmospheric humidity from degrading the freeze-dried peptide structure.
Following reconstitution, liquid stock solutions should be aliquoted into single-use microcentrifuge tubes (polypropylene or low-protein-binding microfuge tubes) to prevent repeated freeze-thaw cycles. Repeated thermal cycling causes physical stress, structural unfolding, and adsorption of the peptide to container walls. Reconstituted aqueous solutions stored at 2°C to 8°C should be utilized within 7 to 14 days, whereas frozen aliquots stored at -20°C remain viable for up to 3 to 6 months depending on the specific buffer system and storage concentration.
Selecting a reliable supplier when evaluating gonadorelin injectable for sale requires careful evaluation of manufacturing standards and batch documentation. Impurities present in low-grade peptide formulations—such as truncated sequence fragments, residual cleavage reagents, or heavy metal catalysts—can distort cell signaling assays and produce false toxicity artifacts in animal models.
PX1 Research ensures strict quality standards through multi-tier analytical verification. Every batch of Gonadorelin undergoes high-performance liquid chromatography (RP-HPLC) to confirm structural purity exceeds 98.0%. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF-MS) or ESI-MS is conducted to verify exact molecular mass against theoretical sequence parameters. Furthermore, chromogenic Limulus Amebocyte Lysate (LAL) testing is performed on every lot to guarantee endotoxin levels remain strictly below <0.01 EU/μg, preventing non-specific inflammatory responses in sensitive cell culture or animal research setups.
Institutional laboratories require predictable turnaround times and consistent lot traceability when procuring peptides for longitudinal studies. PX1 Research operates centralized synthesis, storage, and dispatch centers out of California and Arizona, providing immediate same-day shipping for orders placed before 3:00 PM EST Monday through Friday.
To support high-throughput screening initiatives, academic departments and commercial research laboratories can establish verified institutional accounts. Through our wholesale lab procurement program, research organizations gain access to volume batch manufacturing, custom vial fill quantities, and dedicated quality assurance archives detailing lot-to-lot consistency records.
What is the primary scientific application of Gonadorelin in research?
Gonadorelin is utilized in laboratory research to investigate gonadotropin-releasing hormone receptor (GnRHR) kinetics, intracellular calcium signaling, second messenger pathways (IP3/DAG), and the regulated secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in pituitary cell cultures and animal models.
What purity level is guaranteed for PX1 Research Gonadorelin?
PX1 Research supplies Gonadorelin with a guaranteed purity of ≥98.0%, as confirmed by reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) analysis.
How is the molecular identity of Gonadorelin verified?
Molecular identity is verified using Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF mass spectrometry to confirm that the observed mass matches the theoretical molecular weight of 1182.3 Da.
What diluent should be used to reconstitute lyophilized Gonadorelin?
For acute cell culture assays, sterile saline (0.9% NaCl) or phosphate-buffered saline (PBS) is recommended. For multi-use laboratory stock solutions, sterile bacteriostatic water containing 0.9% benzyl alcohol should be used.
Are endotoxin levels tested for each lot of Gonadorelin?
Yes. Every lot of Gonadorelin undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels measure strictly below <0.01 EU/μg, minimizing confounding immune activation in experimental models.
How should reconstituted Gonadorelin solutions be stored?
Reconstituted solutions should be divided into single-use aliquots and stored at -20°C or -80°C to prevent degradation from repeated freeze-thaw cycles. Short-term storage of working solutions at 2°C to 8°C is acceptable for up to 14 days.
How does native Gonadorelin differ from modified GnRH agonists like Leuprolide?
Native Gonadorelin possesses the wild-type amino acid sequence with a short biological half-life, making it suitable for pulsatile stimulation assays. Modified analogs like leuprolide feature amino acid substitutions (e.g., D-amino acids at position 6) that increase receptor affinity and enzymatic resistance, leading to rapid receptor desensitization.
Where are PX1 Research peptides manufactured and dispatched from?
PX1 Research peptides are synthesized in ISO 17025-accredited, GMP-compliant facilities within the USA and dispatched from fulfillment hubs located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.